S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

Emergent BioSolutions (EBS) Stock Price, News & Analysis

$2.12
-0.37 (-14.86%)
(As of 04:23 PM ET)
Compare
Today's Range
$2.11
$2.48
50-Day Range
$1.82
$3.17
52-Week Range
$1.81
$16.66
Volume
1.60 million shs
Average Volume
1.72 million shs
Market Capitalization
$109.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Emergent BioSolutions MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.50 Rating Score
Upside/​Downside
595.1% Upside
$15.50 Price Target
Short Interest
Bearish
21.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.96) to $2.31 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

486th out of 943 stocks

Pharmaceutical Preparations Industry

208th out of 422 stocks


EBS stock logo

About Emergent BioSolutions Stock (NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Stock Price History

EBS Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Emergent BioSolutions Inc EBS
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Earnings Preview For Emergent BioSolutions
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
12/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$22.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+598.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$-223,800,000.00
Pretax Margin
-67.78%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$0.65 per share
Book Value
$27.72 per share

Miscellaneous

Free Float
50,823,000
Market Cap
$115.01 million
Optionable
Optionable
Beta
1.00
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Richard S. Lindahl M.B.A.Mr. Richard S. Lindahl M.B.A. (Age 59)
    Executive VP, CFO & Treasurer
    Comp: $799.38k
  • Ms. Jennifer L. Fox
    Executive VP of External Affairs, General Counsel & Corporate Secretary
  • Mr. Haywood Miller
    Interim Chief Executive Officer
  • Mr. Robert G. Burrows
    Vice President of Investor Relations
  • Ms. Coleen Glessner
    Executive Vice President of Global Quality and Ethics & Compliance
  • Michelle Pepin
    Senior VP & Chief Human Resource Officer
  • Ms. Stephanie Duatschek
    Senior VP, Chief Strategy & Transformation Officer
  • Dr. Kelly Lyn Warfield
    Senior VP of Science & Development
  • Mr. Paul A. Williams
    Senior Vice President of Products Business
  • William Hartzel
    Senior Vice President of Manufacturing & Bioservices














EBS Stock Analysis - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EBS shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price target for 2024?

2 equities research analysts have issued 12-month price targets for Emergent BioSolutions' stock. Their EBS share price targets range from $9.00 to $22.00. On average, they predict the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 595.1% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2023?

Emergent BioSolutions' stock was trading at $11.81 at the start of the year. Since then, EBS stock has decreased by 81.1% and is now trading at $2.23.
View the best growth stocks for 2023 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 10,930,000 shares, an increase of 21.9% from the October 15th total of 8,970,000 shares. Based on an average daily volume of 2,330,000 shares, the short-interest ratio is currently 4.7 days. Approximately 22.0% of the company's stock are short sold.
View Emergent BioSolutions' Short Interest
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.08. The biopharmaceutical company had revenue of $337.90 million for the quarter, compared to analysts' expectations of $216.17 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 41.78% and a negative net margin of 72.29%. The firm's revenue for the quarter was up 39.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.86) EPS.

What ETF holds Emergent BioSolutions' stock ?

ETFMG Treatments Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (3.01%), Jacobs Levy Equity Management Inc. (2.41%), Northern Trust Corp (0.94%), Allspring Global Investments Holdings LLC (0.88%), Invesco Ltd. (0.58%) and American Century Companies Inc. (0.58%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl, Robert Kramer, Ronald Richard and Sue Bailey.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:EBS) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -